Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

Sanofi India has strongly refuted a recent report claiming the company has initiated the sale or licensing of its flagship insulin brand, Lantus. In a stock exchange filing, Sanofi India said ...